SwanBio Therapeutics, a Bala Cynwyd, Pa.-based gene therapy company developing medicines to deliver clinical efficacy for the treatment of AMN and other neurological diseases, completed a $52m expanded Series A financing.
Syncona Ltd. and Partners Innovation Fund made a $20m investment as part of the additional commitment.
The company intends to use the funds to progress the understanding and development of adeno-associated virus (AAV) based gene therapies, advance manufacturing and development capabilities and allow the execution of its hiring plan to meet the demands of the pipeline.
Led by Tom Anderson, CEO and Director, SwanBio Therapeutics is focused on the development and commercialization of adeno-associated virus (AAV) based gene therapies for the treatment of neurological diseases with significant unmet medical need. The company also has operations in Philadelphia, Pennsylvania and Cambridge, Massachusetts.